nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—melanoma	0.267	0.532	CbGaD
Pomalidomide—PTGS2—melanoma	0.127	0.253	CbGaD
Pomalidomide—ABCB1—melanoma	0.108	0.215	CbGaD
Pomalidomide—CYP1A2—Carmustine—melanoma	0.0621	0.227	CbGbCtD
Pomalidomide—CYP1A2—Vemurafenib—melanoma	0.0491	0.179	CbGbCtD
Pomalidomide—CYP3A4—Temozolomide—melanoma	0.0469	0.172	CbGbCtD
Pomalidomide—CYP1A2—Dacarbazine—melanoma	0.0376	0.138	CbGbCtD
Pomalidomide—ABCB1—Dactinomycin—melanoma	0.0285	0.104	CbGbCtD
Pomalidomide—CYP3A4—Vemurafenib—melanoma	0.0257	0.094	CbGbCtD
Pomalidomide—ABCB1—Docetaxel—melanoma	0.0147	0.0538	CbGbCtD
Pomalidomide—CYP3A4—Docetaxel—melanoma	0.00882	0.0323	CbGbCtD
Pomalidomide—Thalidomide—NFKB1—melanoma	0.00257	0.526	CrCbGaD
Pomalidomide—Thalidomide—TNF—melanoma	0.000788	0.161	CrCbGaD
Pomalidomide—PTGS2—leg—melanoma	0.000752	0.121	CbGeAlD
Pomalidomide—PTGS2—hindlimb—melanoma	0.000672	0.108	CbGeAlD
Pomalidomide—Neuropathy—Carmustine—melanoma	0.000626	0.00551	CcSEcCtD
Pomalidomide—Lenalidomide—PTGS2—melanoma	0.000625	0.128	CrCbGaD
Pomalidomide—Oedema peripheral—Vemurafenib—melanoma	0.000624	0.00549	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Temozolomide—melanoma	0.000622	0.00548	CcSEcCtD
Pomalidomide—Connective tissue disorder—Vemurafenib—melanoma	0.000622	0.00548	CcSEcCtD
Pomalidomide—CRBN—retina—melanoma	0.000621	0.1	CbGeAlD
Pomalidomide—Sepsis—Dactinomycin—melanoma	0.000618	0.00544	CcSEcCtD
Pomalidomide—Interstitial lung disease—Docetaxel—melanoma	0.000605	0.00533	CcSEcCtD
Pomalidomide—Neuropathy—Temozolomide—melanoma	0.000605	0.00533	CcSEcCtD
Pomalidomide—Cardiac disorder—Vemurafenib—melanoma	0.000588	0.00517	CcSEcCtD
Pomalidomide—Sepsis—Carmustine—melanoma	0.000579	0.0051	CcSEcCtD
Pomalidomide—PTGS2—appendage—melanoma	0.000576	0.093	CbGeAlD
Pomalidomide—Angiopathy—Vemurafenib—melanoma	0.000574	0.00506	CcSEcCtD
Pomalidomide—Mediastinal disorder—Vemurafenib—melanoma	0.000571	0.00502	CcSEcCtD
Pomalidomide—Chills—Vemurafenib—melanoma	0.000568	0.005	CcSEcCtD
Pomalidomide—Malnutrition—Vemurafenib—melanoma	0.000551	0.00485	CcSEcCtD
Pomalidomide—Back pain—Vemurafenib—melanoma	0.000533	0.00469	CcSEcCtD
Pomalidomide—Lenalidomide—ABCB1—melanoma	0.000532	0.109	CrCbGaD
Pomalidomide—TNF—lymph node—melanoma	0.000521	0.0842	CbGeAlD
Pomalidomide—CRBN—mammalian vulva—melanoma	0.000497	0.0803	CbGeAlD
Pomalidomide—Hyponatraemia—Carmustine—melanoma	0.000486	0.00428	CcSEcCtD
Pomalidomide—Cough—Vemurafenib—melanoma	0.000481	0.00424	CcSEcCtD
Pomalidomide—PTGS2—skin epidermis—melanoma	0.000479	0.0774	CbGeAlD
Pomalidomide—Hyperbilirubinaemia—Docetaxel—melanoma	0.000471	0.00415	CcSEcCtD
Pomalidomide—Arthralgia—Vemurafenib—melanoma	0.000469	0.00413	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000466	0.0041	CcSEcCtD
Pomalidomide—Pancytopenia—Bleomycin—melanoma	0.000455	0.00401	CcSEcCtD
Pomalidomide—Bone pain—Docetaxel—melanoma	0.000447	0.00394	CcSEcCtD
Pomalidomide—Infection—Vemurafenib—melanoma	0.000447	0.00394	CcSEcCtD
Pomalidomide—Nervous system disorder—Vemurafenib—melanoma	0.000441	0.00388	CcSEcCtD
Pomalidomide—Hypokalaemia—Carmustine—melanoma	0.00044	0.00388	CcSEcCtD
Pomalidomide—Skin disorder—Vemurafenib—melanoma	0.000437	0.00385	CcSEcCtD
Pomalidomide—Dehydration—Temozolomide—melanoma	0.000435	0.00383	CcSEcCtD
Pomalidomide—Weight decreased—Bleomycin—melanoma	0.000434	0.00382	CcSEcCtD
Pomalidomide—Pneumonia—Bleomycin—melanoma	0.00043	0.00378	CcSEcCtD
Pomalidomide—Dry skin—Temozolomide—melanoma	0.000429	0.00378	CcSEcCtD
Pomalidomide—Pulmonary embolism—Docetaxel—melanoma	0.000428	0.00377	CcSEcCtD
Pomalidomide—Muscular weakness—Carmustine—melanoma	0.000427	0.00376	CcSEcCtD
Pomalidomide—Hypokalaemia—Temozolomide—melanoma	0.000426	0.00375	CcSEcCtD
Pomalidomide—Pancytopenia—Dactinomycin—melanoma	0.000424	0.00374	CcSEcCtD
Pomalidomide—Breast disorder—Temozolomide—melanoma	0.000423	0.00372	CcSEcCtD
Pomalidomide—Neutropenia—Dactinomycin—melanoma	0.000418	0.00368	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Temozolomide—melanoma	0.000412	0.00363	CcSEcCtD
Pomalidomide—Muscular weakness—Temozolomide—melanoma	0.000412	0.00363	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00041	0.00361	CcSEcCtD
Pomalidomide—Neuropathy—Docetaxel—melanoma	0.000402	0.00354	CcSEcCtD
Pomalidomide—Pneumonia—Dactinomycin—melanoma	0.000401	0.00353	CcSEcCtD
Pomalidomide—Pancytopenia—Carmustine—melanoma	0.000397	0.0035	CcSEcCtD
Pomalidomide—Neutropenia—Carmustine—melanoma	0.000391	0.00344	CcSEcCtD
Pomalidomide—Decreased appetite—Vemurafenib—melanoma	0.000391	0.00344	CcSEcCtD
Pomalidomide—Bronchitis—Temozolomide—melanoma	0.000389	0.00342	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Vemurafenib—melanoma	0.000388	0.00342	CcSEcCtD
Pomalidomide—Fatigue—Vemurafenib—melanoma	0.000388	0.00342	CcSEcCtD
Pomalidomide—Constipation—Vemurafenib—melanoma	0.000385	0.00339	CcSEcCtD
Pomalidomide—Pancytopenia—Temozolomide—melanoma	0.000384	0.00338	CcSEcCtD
Pomalidomide—Neutropenia—Temozolomide—melanoma	0.000378	0.00333	CcSEcCtD
Pomalidomide—Hyperglycaemia—Carmustine—melanoma	0.000377	0.00332	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Temozolomide—melanoma	0.000376	0.00331	CcSEcCtD
Pomalidomide—Pneumonia—Carmustine—melanoma	0.000375	0.0033	CcSEcCtD
Pomalidomide—Thalidomide—PTGS2—melanoma	0.000374	0.0766	CrCbGaD
Pomalidomide—Sepsis—Docetaxel—melanoma	0.000372	0.00327	CcSEcCtD
Pomalidomide—Weight increased—Temozolomide—melanoma	0.000368	0.00324	CcSEcCtD
Pomalidomide—Renal failure—Carmustine—melanoma	0.000367	0.00323	CcSEcCtD
Pomalidomide—Weight decreased—Temozolomide—melanoma	0.000366	0.00322	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Carmustine—melanoma	0.000366	0.00322	CcSEcCtD
Pomalidomide—Hyperglycaemia—Temozolomide—melanoma	0.000365	0.00321	CcSEcCtD
Pomalidomide—Urinary tract infection—Carmustine—melanoma	0.000363	0.00319	CcSEcCtD
Pomalidomide—Pneumonia—Temozolomide—melanoma	0.000363	0.00319	CcSEcCtD
Pomalidomide—Infestation—Temozolomide—melanoma	0.00036	0.00317	CcSEcCtD
Pomalidomide—Infestation NOS—Temozolomide—melanoma	0.00036	0.00317	CcSEcCtD
Pomalidomide—CRBN—head—melanoma	0.000356	0.0574	CbGeAlD
Pomalidomide—Body temperature increased—Vemurafenib—melanoma	0.000356	0.00313	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Temozolomide—melanoma	0.000353	0.00311	CcSEcCtD
Pomalidomide—Urinary tract infection—Temozolomide—melanoma	0.00035	0.00309	CcSEcCtD
Pomalidomide—PTGS2—endothelium—melanoma	0.000348	0.0561	CbGeAlD
Pomalidomide—Chills—Bleomycin—melanoma	0.000344	0.00303	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Docetaxel—melanoma	0.000343	0.00302	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Temozolomide—melanoma	0.000341	0.003	CcSEcCtD
Pomalidomide—Hypersensitivity—Vemurafenib—melanoma	0.000331	0.00292	CcSEcCtD
Pomalidomide—Oedema peripheral—Carmustine—melanoma	0.00033	0.0029	CcSEcCtD
Pomalidomide—Connective tissue disorder—Carmustine—melanoma	0.000329	0.0029	CcSEcCtD
Pomalidomide—Atrial fibrillation—Docetaxel—melanoma	0.000328	0.00289	CcSEcCtD
Pomalidomide—Asthenia—Vemurafenib—melanoma	0.000323	0.00284	CcSEcCtD
Pomalidomide—Chills—Dactinomycin—melanoma	0.000321	0.00283	CcSEcCtD
Pomalidomide—PTGS2—blood vessel—melanoma	0.000321	0.0518	CbGeAlD
Pomalidomide—Urinary tract disorder—Temozolomide—melanoma	0.00032	0.00281	CcSEcCtD
Pomalidomide—Oedema peripheral—Temozolomide—melanoma	0.000319	0.00281	CcSEcCtD
Pomalidomide—Pruritus—Vemurafenib—melanoma	0.000318	0.0028	CcSEcCtD
Pomalidomide—Connective tissue disorder—Temozolomide—melanoma	0.000318	0.0028	CcSEcCtD
Pomalidomide—Urethral disorder—Temozolomide—melanoma	0.000317	0.00279	CcSEcCtD
Pomalidomide—Hyponatraemia—Docetaxel—melanoma	0.000312	0.00275	CcSEcCtD
Pomalidomide—Pain in extremity—Docetaxel—melanoma	0.000311	0.00274	CcSEcCtD
Pomalidomide—Anaemia—Bleomycin—melanoma	0.000309	0.00272	CcSEcCtD
Pomalidomide—Diarrhoea—Vemurafenib—melanoma	0.000308	0.00271	CcSEcCtD
Pomalidomide—Cardiac disorder—Temozolomide—melanoma	0.0003	0.00264	CcSEcCtD
Pomalidomide—Leukopenia—Bleomycin—melanoma	0.000299	0.00263	CcSEcCtD
Pomalidomide—Dizziness—Vemurafenib—melanoma	0.000297	0.00262	CcSEcCtD
Pomalidomide—Angiopathy—Temozolomide—melanoma	0.000294	0.00259	CcSEcCtD
Pomalidomide—Mental disorder—Carmustine—melanoma	0.000293	0.00258	CcSEcCtD
Pomalidomide—Mediastinal disorder—Temozolomide—melanoma	0.000292	0.00257	CcSEcCtD
Pomalidomide—Malnutrition—Carmustine—melanoma	0.000291	0.00257	CcSEcCtD
Pomalidomide—Cough—Bleomycin—melanoma	0.000291	0.00257	CcSEcCtD
Pomalidomide—Chills—Temozolomide—melanoma	0.00029	0.00256	CcSEcCtD
Pomalidomide—Dehydration—Docetaxel—melanoma	0.000289	0.00255	CcSEcCtD
Pomalidomide—Anaemia—Dactinomycin—melanoma	0.000288	0.00253	CcSEcCtD
Pomalidomide—Vomiting—Vemurafenib—melanoma	0.000286	0.00252	CcSEcCtD
Pomalidomide—Dry skin—Docetaxel—melanoma	0.000285	0.00251	CcSEcCtD
Pomalidomide—Rash—Vemurafenib—melanoma	0.000284	0.0025	CcSEcCtD
Pomalidomide—Mental disorder—Temozolomide—melanoma	0.000283	0.0025	CcSEcCtD
Pomalidomide—Dermatitis—Vemurafenib—melanoma	0.000283	0.0025	CcSEcCtD
Pomalidomide—Back pain—Carmustine—melanoma	0.000282	0.00248	CcSEcCtD
Pomalidomide—Headache—Vemurafenib—melanoma	0.000282	0.00248	CcSEcCtD
Pomalidomide—Malnutrition—Temozolomide—melanoma	0.000282	0.00248	CcSEcCtD
Pomalidomide—Breast disorder—Docetaxel—melanoma	0.000281	0.00248	CcSEcCtD
Pomalidomide—Leukopenia—Dactinomycin—melanoma	0.000279	0.00245	CcSEcCtD
Pomalidomide—Nasopharyngitis—Docetaxel—melanoma	0.000278	0.00245	CcSEcCtD
Pomalidomide—Confusional state—Bleomycin—melanoma	0.000275	0.00242	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Docetaxel—melanoma	0.000274	0.00242	CcSEcCtD
Pomalidomide—Tremor—Carmustine—melanoma	0.000273	0.0024	CcSEcCtD
Pomalidomide—Back pain—Temozolomide—melanoma	0.000272	0.0024	CcSEcCtD
Pomalidomide—Infection—Bleomycin—melanoma	0.000271	0.00238	CcSEcCtD
Pomalidomide—Anaemia—Carmustine—melanoma	0.000269	0.00237	CcSEcCtD
Pomalidomide—Nausea—Vemurafenib—melanoma	0.000267	0.00235	CcSEcCtD
Pomalidomide—Thrombocytopenia—Bleomycin—melanoma	0.000267	0.00235	CcSEcCtD
Pomalidomide—Tremor—Temozolomide—melanoma	0.000264	0.00232	CcSEcCtD
Pomalidomide—Leukopenia—Carmustine—melanoma	0.000261	0.0023	CcSEcCtD
Pomalidomide—Anaemia—Temozolomide—melanoma	0.00026	0.00229	CcSEcCtD
Pomalidomide—Pancytopenia—Docetaxel—melanoma	0.000255	0.00225	CcSEcCtD
Pomalidomide—Vertigo—Temozolomide—melanoma	0.000253	0.00223	CcSEcCtD
Pomalidomide—Infection—Dactinomycin—melanoma	0.000252	0.00222	CcSEcCtD
Pomalidomide—Leukopenia—Temozolomide—melanoma	0.000252	0.00222	CcSEcCtD
Pomalidomide—Neutropenia—Docetaxel—melanoma	0.000251	0.00221	CcSEcCtD
Pomalidomide—CRBN—lymph node—melanoma	0.000249	0.0402	CbGeAlD
Pomalidomide—Thrombocytopenia—Dactinomycin—melanoma	0.000249	0.00219	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Bleomycin—melanoma	0.000248	0.00219	CcSEcCtD
Pomalidomide—Anxiety—Carmustine—melanoma	0.000247	0.00218	CcSEcCtD
Pomalidomide—Cough—Temozolomide—melanoma	0.000246	0.00216	CcSEcCtD
Pomalidomide—Weight increased—Docetaxel—melanoma	0.000245	0.00215	CcSEcCtD
Pomalidomide—Weight decreased—Docetaxel—melanoma	0.000243	0.00214	CcSEcCtD
Pomalidomide—Dyspnoea—Bleomycin—melanoma	0.000243	0.00214	CcSEcCtD
Pomalidomide—Pneumonia—Docetaxel—melanoma	0.000241	0.00212	CcSEcCtD
Pomalidomide—Confusional state—Carmustine—melanoma	0.00024	0.00211	CcSEcCtD
Pomalidomide—Arthralgia—Temozolomide—melanoma	0.00024	0.00211	CcSEcCtD
Pomalidomide—Infestation NOS—Docetaxel—melanoma	0.00024	0.00211	CcSEcCtD
Pomalidomide—Infestation—Docetaxel—melanoma	0.00024	0.00211	CcSEcCtD
Pomalidomide—Anxiety—Temozolomide—melanoma	0.000239	0.0021	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000238	0.0021	CcSEcCtD
Pomalidomide—Decreased appetite—Bleomycin—melanoma	0.000237	0.00209	CcSEcCtD
Pomalidomide—Infection—Carmustine—melanoma	0.000236	0.00208	CcSEcCtD
Pomalidomide—Renal failure—Docetaxel—melanoma	0.000236	0.00207	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Docetaxel—melanoma	0.000235	0.00207	CcSEcCtD
Pomalidomide—Pain—Bleomycin—melanoma	0.000233	0.00205	CcSEcCtD
Pomalidomide—Thrombocytopenia—Carmustine—melanoma	0.000233	0.00205	CcSEcCtD
Pomalidomide—Confusional state—Temozolomide—melanoma	0.000232	0.00204	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000232	0.00204	CcSEcCtD
Pomalidomide—Infection—Temozolomide—melanoma	0.000228	0.00201	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Docetaxel—melanoma	0.000227	0.002	CcSEcCtD
Pomalidomide—Epistaxis—Docetaxel—melanoma	0.000226	0.00199	CcSEcCtD
Pomalidomide—Nervous system disorder—Temozolomide—melanoma	0.000225	0.00199	CcSEcCtD
Pomalidomide—Thrombocytopenia—Temozolomide—melanoma	0.000225	0.00198	CcSEcCtD
Pomalidomide—Feeling abnormal—Bleomycin—melanoma	0.000225	0.00198	CcSEcCtD
Pomalidomide—Skin disorder—Temozolomide—melanoma	0.000223	0.00197	CcSEcCtD
Pomalidomide—Hyperhidrosis—Temozolomide—melanoma	0.000222	0.00196	CcSEcCtD
Pomalidomide—Decreased appetite—Dactinomycin—melanoma	0.000221	0.00195	CcSEcCtD
Pomalidomide—Fatigue—Dactinomycin—melanoma	0.000219	0.00193	CcSEcCtD
Pomalidomide—Pain—Dactinomycin—melanoma	0.000217	0.00191	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Carmustine—melanoma	0.000217	0.00191	CcSEcCtD
Pomalidomide—Body temperature increased—Bleomycin—melanoma	0.000215	0.0019	CcSEcCtD
Pomalidomide—Insomnia—Carmustine—melanoma	0.000215	0.00189	CcSEcCtD
Pomalidomide—Urinary tract disorder—Docetaxel—melanoma	0.000212	0.00187	CcSEcCtD
Pomalidomide—Dyspnoea—Carmustine—melanoma	0.000212	0.00187	CcSEcCtD
Pomalidomide—Oedema peripheral—Docetaxel—melanoma	0.000212	0.00187	CcSEcCtD
Pomalidomide—Connective tissue disorder—Docetaxel—melanoma	0.000211	0.00186	CcSEcCtD
Pomalidomide—Urethral disorder—Docetaxel—melanoma	0.000211	0.00186	CcSEcCtD
Pomalidomide—Feeling abnormal—Dactinomycin—melanoma	0.000209	0.00184	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Temozolomide—melanoma	0.000209	0.00184	CcSEcCtD
Pomalidomide—Insomnia—Temozolomide—melanoma	0.000208	0.00183	CcSEcCtD
Pomalidomide—Decreased appetite—Carmustine—melanoma	0.000207	0.00182	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Carmustine—melanoma	0.000205	0.00181	CcSEcCtD
Pomalidomide—Dyspnoea—Temozolomide—melanoma	0.000205	0.0018	CcSEcCtD
Pomalidomide—Pain—Carmustine—melanoma	0.000203	0.00179	CcSEcCtD
Pomalidomide—Constipation—Carmustine—melanoma	0.000203	0.00179	CcSEcCtD
Pomalidomide—Body temperature increased—Dactinomycin—melanoma	0.000201	0.00177	CcSEcCtD
Pomalidomide—Hypersensitivity—Bleomycin—melanoma	0.000201	0.00177	CcSEcCtD
Pomalidomide—Decreased appetite—Temozolomide—melanoma	0.0002	0.00176	CcSEcCtD
Pomalidomide—Cardiac disorder—Docetaxel—melanoma	0.0002	0.00176	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Temozolomide—melanoma	0.000198	0.00175	CcSEcCtD
Pomalidomide—ABCB1—blood vessel—melanoma	0.000198	0.032	CbGeAlD
Pomalidomide—Fatigue—Temozolomide—melanoma	0.000198	0.00175	CcSEcCtD
Pomalidomide—Pain—Temozolomide—melanoma	0.000197	0.00173	CcSEcCtD
Pomalidomide—Constipation—Temozolomide—melanoma	0.000197	0.00173	CcSEcCtD
Pomalidomide—Feeling abnormal—Carmustine—melanoma	0.000196	0.00173	CcSEcCtD
Pomalidomide—Asthenia—Bleomycin—melanoma	0.000196	0.00172	CcSEcCtD
Pomalidomide—Angiopathy—Docetaxel—melanoma	0.000195	0.00172	CcSEcCtD
Pomalidomide—Mediastinal disorder—Docetaxel—melanoma	0.000194	0.00171	CcSEcCtD
Pomalidomide—Chills—Docetaxel—melanoma	0.000193	0.0017	CcSEcCtD
Pomalidomide—Pruritus—Bleomycin—melanoma	0.000193	0.0017	CcSEcCtD
Pomalidomide—Feeling abnormal—Temozolomide—melanoma	0.000189	0.00167	CcSEcCtD
Pomalidomide—Mental disorder—Docetaxel—melanoma	0.000189	0.00166	CcSEcCtD
Pomalidomide—Body temperature increased—Carmustine—melanoma	0.000188	0.00166	CcSEcCtD
Pomalidomide—Malnutrition—Docetaxel—melanoma	0.000187	0.00165	CcSEcCtD
Pomalidomide—Hypersensitivity—Dactinomycin—melanoma	0.000187	0.00165	CcSEcCtD
Pomalidomide—Asthenia—Dactinomycin—melanoma	0.000182	0.00161	CcSEcCtD
Pomalidomide—Body temperature increased—Temozolomide—melanoma	0.000182	0.0016	CcSEcCtD
Pomalidomide—Back pain—Docetaxel—melanoma	0.000181	0.0016	CcSEcCtD
Pomalidomide—Muscle spasms—Docetaxel—melanoma	0.00018	0.00159	CcSEcCtD
Pomalidomide—Hypersensitivity—Carmustine—melanoma	0.000175	0.00154	CcSEcCtD
Pomalidomide—Diarrhoea—Dactinomycin—melanoma	0.000174	0.00153	CcSEcCtD
Pomalidomide—Vomiting—Bleomycin—melanoma	0.000173	0.00153	CcSEcCtD
Pomalidomide—Anaemia—Docetaxel—melanoma	0.000173	0.00152	CcSEcCtD
Pomalidomide—Rash—Bleomycin—melanoma	0.000172	0.00151	CcSEcCtD
Pomalidomide—Dermatitis—Bleomycin—melanoma	0.000172	0.00151	CcSEcCtD
Pomalidomide—Asthenia—Carmustine—melanoma	0.000171	0.0015	CcSEcCtD
Pomalidomide—Hypersensitivity—Temozolomide—melanoma	0.000169	0.00149	CcSEcCtD
Pomalidomide—Leukopenia—Docetaxel—melanoma	0.000168	0.00148	CcSEcCtD
Pomalidomide—Asthenia—Temozolomide—melanoma	0.000165	0.00145	CcSEcCtD
Pomalidomide—Cough—Docetaxel—melanoma	0.000163	0.00144	CcSEcCtD
Pomalidomide—Diarrhoea—Carmustine—melanoma	0.000163	0.00143	CcSEcCtD
Pomalidomide—Pruritus—Temozolomide—melanoma	0.000163	0.00143	CcSEcCtD
Pomalidomide—Nausea—Bleomycin—melanoma	0.000162	0.00143	CcSEcCtD
Pomalidomide—Vomiting—Dactinomycin—melanoma	0.000162	0.00142	CcSEcCtD
Pomalidomide—Rash—Dactinomycin—melanoma	0.00016	0.00141	CcSEcCtD
Pomalidomide—Arthralgia—Docetaxel—melanoma	0.000159	0.0014	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000158	0.00139	CcSEcCtD
Pomalidomide—Dizziness—Carmustine—melanoma	0.000157	0.00139	CcSEcCtD
Pomalidomide—Diarrhoea—Temozolomide—melanoma	0.000157	0.00139	CcSEcCtD
Pomalidomide—Confusional state—Docetaxel—melanoma	0.000154	0.00136	CcSEcCtD
Pomalidomide—Dizziness—Temozolomide—melanoma	0.000152	0.00134	CcSEcCtD
Pomalidomide—Infection—Docetaxel—melanoma	0.000152	0.00134	CcSEcCtD
Pomalidomide—Vomiting—Carmustine—melanoma	0.000151	0.00133	CcSEcCtD
Pomalidomide—Nausea—Dactinomycin—melanoma	0.000151	0.00133	CcSEcCtD
Pomalidomide—Rash—Carmustine—melanoma	0.00015	0.00132	CcSEcCtD
Pomalidomide—Nervous system disorder—Docetaxel—melanoma	0.00015	0.00132	CcSEcCtD
Pomalidomide—Dermatitis—Carmustine—melanoma	0.00015	0.00132	CcSEcCtD
Pomalidomide—Thrombocytopenia—Docetaxel—melanoma	0.00015	0.00132	CcSEcCtD
Pomalidomide—Headache—Carmustine—melanoma	0.000149	0.00131	CcSEcCtD
Pomalidomide—PTGS2—skin of body—melanoma	0.000149	0.024	CbGeAlD
Pomalidomide—Skin disorder—Docetaxel—melanoma	0.000148	0.00131	CcSEcCtD
Pomalidomide—Vomiting—Temozolomide—melanoma	0.000146	0.00129	CcSEcCtD
Pomalidomide—Rash—Temozolomide—melanoma	0.000145	0.00128	CcSEcCtD
Pomalidomide—Dermatitis—Temozolomide—melanoma	0.000145	0.00128	CcSEcCtD
Pomalidomide—Headache—Temozolomide—melanoma	0.000144	0.00127	CcSEcCtD
Pomalidomide—Nausea—Carmustine—melanoma	0.000141	0.00124	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Docetaxel—melanoma	0.000139	0.00123	CcSEcCtD
Pomalidomide—Insomnia—Docetaxel—melanoma	0.000138	0.00122	CcSEcCtD
Pomalidomide—Nausea—Temozolomide—melanoma	0.000137	0.0012	CcSEcCtD
Pomalidomide—Dyspnoea—Docetaxel—melanoma	0.000136	0.0012	CcSEcCtD
Pomalidomide—Decreased appetite—Docetaxel—melanoma	0.000133	0.00117	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Docetaxel—melanoma	0.000132	0.00116	CcSEcCtD
Pomalidomide—Fatigue—Docetaxel—melanoma	0.000132	0.00116	CcSEcCtD
Pomalidomide—Pain—Docetaxel—melanoma	0.000131	0.00115	CcSEcCtD
Pomalidomide—Constipation—Docetaxel—melanoma	0.000131	0.00115	CcSEcCtD
Pomalidomide—Feeling abnormal—Docetaxel—melanoma	0.000126	0.00111	CcSEcCtD
Pomalidomide—Body temperature increased—Docetaxel—melanoma	0.000121	0.00106	CcSEcCtD
Pomalidomide—Hypersensitivity—Docetaxel—melanoma	0.000113	0.000992	CcSEcCtD
Pomalidomide—Asthenia—Docetaxel—melanoma	0.00011	0.000966	CcSEcCtD
Pomalidomide—Pruritus—Docetaxel—melanoma	0.000108	0.000952	CcSEcCtD
Pomalidomide—ABCB1—retina—melanoma	0.000105	0.0169	CbGeAlD
Pomalidomide—Diarrhoea—Docetaxel—melanoma	0.000105	0.000921	CcSEcCtD
Pomalidomide—Dizziness—Docetaxel—melanoma	0.000101	0.00089	CcSEcCtD
Pomalidomide—Vomiting—Docetaxel—melanoma	9.72e-05	0.000856	CcSEcCtD
Pomalidomide—PTGS2—head—melanoma	9.69e-05	0.0156	CbGeAlD
Pomalidomide—Rash—Docetaxel—melanoma	9.64e-05	0.000849	CcSEcCtD
Pomalidomide—Dermatitis—Docetaxel—melanoma	9.63e-05	0.000848	CcSEcCtD
Pomalidomide—Headache—Docetaxel—melanoma	9.58e-05	0.000843	CcSEcCtD
Pomalidomide—Nausea—Docetaxel—melanoma	9.08e-05	0.0008	CcSEcCtD
Pomalidomide—ABCB1—mammalian vulva—melanoma	8.38e-05	0.0135	CbGeAlD
Pomalidomide—PTGS2—lymph node—melanoma	6.78e-05	0.011	CbGeAlD
Pomalidomide—ABCB1—head—melanoma	5.99e-05	0.00967	CbGeAlD
Pomalidomide—ABCB1—lymph node—melanoma	4.2e-05	0.00677	CbGeAlD
Pomalidomide—PTGS2—Metabolism—HPSE—melanoma	1.83e-05	0.000181	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	1.82e-05	0.000181	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	1.81e-05	0.00018	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CUBN—melanoma	1.79e-05	0.000178	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	1.79e-05	0.000178	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—melanoma	1.76e-05	0.000175	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	1.74e-05	0.000172	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	1.73e-05	0.000172	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SDHD—melanoma	1.73e-05	0.000172	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—BSG—melanoma	1.73e-05	0.000172	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CSPG4—melanoma	1.73e-05	0.000172	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HS3ST5—melanoma	1.7e-05	0.000169	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ERBB2—melanoma	1.7e-05	0.000169	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPAM—melanoma	1.68e-05	0.000166	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HDAC6—melanoma	1.65e-05	0.000164	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	1.64e-05	0.000163	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	1.64e-05	0.000163	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	1.62e-05	0.000161	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLCB4—melanoma	1.62e-05	0.000161	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	1.6e-05	0.000158	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—melanoma	1.6e-05	0.000158	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NPPA—melanoma	1.57e-05	0.000155	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	1.56e-05	0.000155	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	1.56e-05	0.000155	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	1.56e-05	0.000155	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ACER3—melanoma	1.55e-05	0.000154	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—VCAN—melanoma	1.53e-05	0.000152	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC6A11—melanoma	1.52e-05	0.000151	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIP4K2A—melanoma	1.52e-05	0.000151	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—WNT5A—melanoma	1.52e-05	0.00015	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CTNNB1—melanoma	1.49e-05	0.000148	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—melanoma	1.49e-05	0.000148	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—melanoma	1.49e-05	0.000147	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTAP—melanoma	1.48e-05	0.000147	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	1.48e-05	0.000147	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	1.48e-05	0.000146	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—melanoma	1.46e-05	0.000145	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	1.45e-05	0.000144	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NFKB1—melanoma	1.45e-05	0.000143	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PLA2G6—melanoma	1.43e-05	0.000141	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—UGT2B10—melanoma	1.42e-05	0.00014	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	1.41e-05	0.00014	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	1.4e-05	0.000139	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	1.37e-05	0.000136	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	1.37e-05	0.000135	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	1.36e-05	0.000135	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	1.36e-05	0.000134	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	1.36e-05	0.000134	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PHGDH—melanoma	1.32e-05	0.000131	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—LUM—melanoma	1.32e-05	0.000131	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HS3ST5—melanoma	1.32e-05	0.000131	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—melanoma	1.31e-05	0.00013	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—melanoma	1.31e-05	0.00013	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—STAT3—melanoma	1.3e-05	0.000129	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NRAS—melanoma	1.3e-05	0.000129	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HPSE—melanoma	1.29e-05	0.000128	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLCB4—melanoma	1.29e-05	0.000128	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—VCAN—melanoma	1.28e-05	0.000127	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CUBN—melanoma	1.27e-05	0.000126	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—FASN—melanoma	1.27e-05	0.000126	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MAPK3—melanoma	1.24e-05	0.000123	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	1.23e-05	0.000122	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SDHD—melanoma	1.23e-05	0.000122	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—BSG—melanoma	1.23e-05	0.000122	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CSPG4—melanoma	1.23e-05	0.000122	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GAB2—melanoma	1.22e-05	0.000121	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC6A11—melanoma	1.21e-05	0.000121	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIP4K2A—melanoma	1.21e-05	0.000121	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.21e-05	0.00012	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FASN—melanoma	1.19e-05	0.000118	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPAM—melanoma	1.19e-05	0.000118	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTAP—melanoma	1.18e-05	0.000117	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MAPK1—melanoma	1.18e-05	0.000117	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—melanoma	1.18e-05	0.000117	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.17e-05	0.000116	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	1.16e-05	0.000115	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	1.16e-05	0.000115	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FOXO4—melanoma	1.14e-05	0.000114	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CXCR4—melanoma	1.14e-05	0.000114	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HDAC2—melanoma	1.14e-05	0.000114	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD44—melanoma	1.13e-05	0.000112	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	1.13e-05	0.000112	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—melanoma	1.12e-05	0.000111	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	1.11e-05	0.00011	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	1.11e-05	0.00011	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	1.11e-05	0.00011	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP17A1—melanoma	1.08e-05	0.000107	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.07e-05	0.000106	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	1.05e-05	0.000105	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PHGDH—melanoma	1.05e-05	0.000105	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—LUM—melanoma	1.05e-05	0.000105	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—melanoma	1.05e-05	0.000104	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	1.05e-05	0.000104	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT3—melanoma	1.04e-05	0.000104	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HPSE—melanoma	1.03e-05	0.000102	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNA11—melanoma	1.02e-05	0.000101	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CUBN—melanoma	1.01e-05	0.000101	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PLA2G6—melanoma	1.01e-05	0.0001	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—FASN—melanoma	9.98e-06	9.9e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLCB4—melanoma	9.97e-06	9.89e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC5A5—melanoma	9.82e-06	9.74e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SDHD—melanoma	9.79e-06	9.72e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—BSG—melanoma	9.79e-06	9.72e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CSPG4—melanoma	9.79e-06	9.72e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	9.61e-06	9.53e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPAM—melanoma	9.48e-06	9.41e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CD44—melanoma	9.48e-06	9.41e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNAQ—melanoma	9.48e-06	9.41e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—melanoma	9.48e-06	9.41e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC6A11—melanoma	9.38e-06	9.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIP4K2A—melanoma	9.38e-06	9.3e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	9.29e-06	9.22e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	9.28e-06	9.21e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB4—melanoma	9.23e-06	9.16e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN2B—melanoma	9.15e-06	9.08e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTAP—melanoma	9.12e-06	9.05e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1B1—melanoma	9.09e-06	9.02e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—VCAN—melanoma	9.07e-06	9e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—melanoma	9.07e-06	9e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD86—melanoma	8.85e-06	8.78e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF1—melanoma	8.58e-06	8.51e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—melanoma	8.37e-06	8.3e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFRA—melanoma	8.31e-06	8.24e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PRKCA—melanoma	8.23e-06	8.16e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERCC2—melanoma	8.16e-06	8.09e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PHGDH—melanoma	8.13e-06	8.07e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—LUM—melanoma	8.13e-06	8.07e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PLA2G6—melanoma	8.06e-06	8e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAP2K2—melanoma	8.04e-06	7.98e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	8.02e-06	7.96e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HPSE—melanoma	7.97e-06	7.91e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	7.85e-06	7.79e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CUBN—melanoma	7.83e-06	7.76e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP17A1—melanoma	7.66e-06	7.6e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—melanoma	7.65e-06	7.59e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HLA-A—melanoma	7.65e-06	7.59e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RAC1—melanoma	7.63e-06	7.57e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SDHD—melanoma	7.56e-06	7.5e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—BSG—melanoma	7.56e-06	7.5e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CSPG4—melanoma	7.56e-06	7.5e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCB1—melanoma	7.49e-06	7.43e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPAM—melanoma	7.32e-06	7.26e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HIF1A—melanoma	7.31e-06	7.26e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—VCAN—melanoma	7.24e-06	7.19e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNA11—melanoma	7.23e-06	7.17e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	7.09e-06	7.03e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—FASN—melanoma	7.07e-06	7.02e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC5A5—melanoma	6.96e-06	6.9e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PRKCA—melanoma	6.89e-06	6.83e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	6.86e-06	6.8e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ERCC2—melanoma	6.83e-06	6.78e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNAQ—melanoma	6.72e-06	6.67e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CD44—melanoma	6.72e-06	6.67e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS2—melanoma	6.65e-06	6.6e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	6.62e-06	6.57e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOTCH1—melanoma	6.59e-06	6.54e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD80—melanoma	6.45e-06	6.4e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1B1—melanoma	6.44e-06	6.39e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APC—melanoma	6.44e-06	6.39e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KIT—melanoma	6.44e-06	6.39e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGF—melanoma	6.37e-06	6.32e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PLA2G6—melanoma	6.22e-06	6.17e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP17A1—melanoma	6.11e-06	6.06e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BRAF—melanoma	6.06e-06	6.01e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	6.03e-06	5.98e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	5.95e-06	5.9e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNA11—melanoma	5.77e-06	5.73e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAP2K1—melanoma	5.7e-06	5.66e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CD—melanoma	5.66e-06	5.62e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.66e-06	5.62e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—FASN—melanoma	5.65e-06	5.6e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—VCAN—melanoma	5.59e-06	5.55e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC5A5—melanoma	5.56e-06	5.51e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF2—melanoma	5.42e-06	5.38e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CG—melanoma	5.4e-06	5.35e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNAQ—melanoma	5.37e-06	5.32e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CD44—melanoma	5.37e-06	5.32e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	5.25e-06	5.21e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARG—melanoma	5.21e-06	5.17e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	5.21e-06	5.16e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1B1—melanoma	5.14e-06	5.1e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MDM2—melanoma	5.07e-06	5.03e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ERBB2—melanoma	5e-06	4.96e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CB—melanoma	4.94e-06	4.9e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—melanoma	4.93e-06	4.89e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PRKCA—melanoma	4.88e-06	4.84e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ERCC2—melanoma	4.84e-06	4.81e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CD—melanoma	4.74e-06	4.71e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP17A1—melanoma	4.72e-06	4.68e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—melanoma	4.68e-06	4.65e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—melanoma	4.63e-06	4.6e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	4.54e-06	4.5e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNA11—melanoma	4.45e-06	4.42e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CTNNB1—melanoma	4.38e-06	4.34e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—FASN—melanoma	4.36e-06	4.32e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC5A5—melanoma	4.29e-06	4.25e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—melanoma	4.28e-06	4.24e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—melanoma	4.27e-06	4.23e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCB1—melanoma	4.24e-06	4.2e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNAQ—melanoma	4.14e-06	4.11e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CD44—melanoma	4.14e-06	4.11e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CB—melanoma	4.13e-06	4.1e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1B1—melanoma	3.97e-06	3.94e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PRKCA—melanoma	3.9e-06	3.87e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ERCC2—melanoma	3.87e-06	3.84e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CG—melanoma	3.83e-06	3.79e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—melanoma	3.82e-06	3.79e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRAS—melanoma	3.81e-06	3.78e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARG—melanoma	3.69e-06	3.66e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK3—melanoma	3.65e-06	3.62e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—melanoma	3.57e-06	3.54e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—melanoma	3.55e-06	3.52e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK1—melanoma	3.47e-06	3.44e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—melanoma	3.47e-06	3.44e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CD—melanoma	3.36e-06	3.34e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—melanoma	3.32e-06	3.29e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—melanoma	3.28e-06	3.25e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCB1—melanoma	3.27e-06	3.24e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.2e-06	3.18e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CG—melanoma	3.05e-06	3.03e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—melanoma	3.01e-06	2.99e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PRKCA—melanoma	3.01e-06	2.99e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ERCC2—melanoma	2.98e-06	2.96e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARG—melanoma	2.95e-06	2.92e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CB—melanoma	2.93e-06	2.91e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—melanoma	2.9e-06	2.88e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—melanoma	2.78e-06	2.76e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CD—melanoma	2.68e-06	2.66e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—melanoma	2.67e-06	2.64e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—melanoma	2.65e-06	2.63e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—melanoma	2.53e-06	2.51e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—melanoma	2.52e-06	2.5e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—melanoma	2.46e-06	2.44e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CG—melanoma	2.36e-06	2.34e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CB—melanoma	2.34e-06	2.32e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—melanoma	2.32e-06	2.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARG—melanoma	2.27e-06	2.26e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CD—melanoma	2.07e-06	2.06e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—melanoma	2.06e-06	2.04e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—melanoma	2.05e-06	2.03e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—melanoma	2.02e-06	2.01e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CB—melanoma	1.81e-06	1.79e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—melanoma	1.79e-06	1.78e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—melanoma	1.79e-06	1.77e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—melanoma	1.56e-06	1.55e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—melanoma	1.46e-06	1.45e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—melanoma	1.43e-06	1.42e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—melanoma	1.17e-06	1.16e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—melanoma	1.1e-06	1.09e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—melanoma	8.99e-07	8.92e-06	CbGpPWpGaD
